Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc.

CGEM·NASDAQ

$15.12

-1.4%
HealthcareMedical - Pharmaceuticals

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

At a Glance

Live Snapshot
Market Cap$929.55M
EPS-3.7200
P/E Ratio-4.07
Earnings Date08/06/2026

cgem

Sales/Maturities of Investments

Last Annual Value

416.57M

3-Year CAGR

6%

5-Year CAGR

46%

10-Year CAGR

%

Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc. Competitors Analysis of Sales/Maturities of Investments

CGEM · NASDAQ
CompanySales/Maturities of Investments
CAGR 3Y
CAGR 5Y
CAGR 10Y
416.57M
0.6%16.8%N/A 
65.40M
32.2%N/AN/A
CBLL logo
CeriBell, Inc.
NASDAQ:CBLL
94.20M
N/AN/AN/A
EHAB logo
Enhabit, Inc.
NYSE:EHAB
1.80M
N/AN/AN/A
179.00M
14.9%N/A7.6%
251.17M
12.1%N/AN/A
135.04M
-20.3%9.9%N/A
109.90M
-52.8%1.9%6.6%
Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc. Fair Value Envelope

CGEM · NASDAQ

Our analysis suggests that CGEM has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $15.125, this represents a potential HIDDEN relative to our calculated worth for Cullinan Therapeutics, Inc..

Intrinsic Value
Current Price: $15.125